Richard Gilbertson elected to EMBO membership
Senior Group Leader,Ā Professor Richard Gilbertson, has been elected a member of the European Molecular Biology Organisation (EMBO) in recognition of his high-quality life science research.
Gilbertson is one of 67 life scientists to be elected this year, joining the community of more than 1,900 members in Europe and beyond.
āThe new EMBO Members and Associate Members are exceptional scientists, who carry out leading research across a variety of fields, ranging from cell biology and cancer to vaccine development and machine learning,ā says EMBO Director Fiona Watt. āI am delighted to welcome them to EMBO, and I know that they will enrich the life of the organization immensely.ā
Professor Richard Gilbertson said āIt is such an honour to have been elected toĀ EMBOĀ and be part of this incredible group of scientists and colleagues from across Europe. I very much hope to continue to promote international collaborations and interactions through my membership of this terrific organisation.ā
Members provide guidance and support for EMBO activities, for example by evaluating funding applications, serving on EMBO Council and committees, or joining the editorial boards of EMBO Press journals. Through their involvement, members help to shape the direction of life sciences, foster the careers of young researchers, and strengthen the research communities in Europe and beyond.
New members are nominated and elected by the existing EMBO Membership. The annual process ensures a broad scope with the flexibility to expand into newly emerging fields in the life sciences.
EMBO will formally welcome the new members at the annual Membersā Meeting in Heidelberg between 26 and 28 October 2022.
An online directory listing all members, their affiliations, and subject areas is availableĀ here.
Related News
See all news-
Dr Richard Mair to co-lead £13.7M investment for brain tumour research
19th December 2025
The National Institute for Health and Care Research (NIHR) has today announced a £13.7 million investment that will support ground-breaking research to develop novel brain tumour treatments in the UK.
Find out more -
Order of cancer-driving mutations affects the chance of tumour developmentĀ
3rd December 2025
New research from the Winton Group has revealed that the order of cancer-driving mutations plays an important role in whether tumours in the intestine can develop.
Find out more -
Cancer Detectives: New Channel 4 Documentary Showcases Cambridge Brain Cancer Trial
27th November 2025
A Cambridge researcher offering new hope to people with brain tumours is the focus of a documentary exploring the science behind the next big breakthroughs.
Find out more